Provided herein are methods for detecting an estrogen-induced cancer in a subject, for identifying a subject at risk of developing an estrogen-induced cancer and for determining or predicting prognosis for a subject with an estrogen-induced cancer. The methods of the disclosure comprise determining the level of expression of ALPPL2 in a biological sample, typically a blood sample, obtained from a subject.

The present inventors have developed antigen-binding reagents and antigen-binding conjugates that recognize a cancer-specific glycan (carbohydrate) modification on the human Periostin protein. Various in vitro and in vivo diagnostic and/or therapeutic methods using these compositions are also disclosed herein specifically for treating cancers that have amplification of the Mgat3 gene.

Disclosed is a method for assisting a determination of an efficacy of an immune checkpoint inhibitor, the method comprising: measuring a free protein marker in a liquid sample collected from a subject; and determining the efficacy of the immune checkpoint inhibitor in the subject based on a result of the measurement, wherein the free protein marker is at least one selected from free Cytotoxic T lymphocyte antigen-4 (CTLA-4), free Programmed cell death-1 (PD-1) and free Programmed cell death-ligand 1 (PD-L1).

This invention provides devices and methods for self-administered noninvasive retrieval of biological materials of the uterus and cervix, and preimplantation stage embryos. The procedure uses a Uterine Device, with a receptacle of variable volume, a controller configured to change the volume of the receptacle cavity, a flexible pouch for generation of suction to facilitate their retrieval, and an Absorption Capsule, which is a surface for collection of the above biological materials. The biological materials retrieved include cells and secretions, directly from the site of pathology, not metabolized or diluted in the body fluids, allow comprehensive analysis of various biomarkers of diseases and disorders of reproduction. Information generated by analyzing these biological materials permits early diagnosis and assessment of prognosis of diseases and disorders of the female reproductive organs, irregularities of pregnancy, anomalies of the fetus in utero, and microbial infections. The preimplantation stage embryos are recovered from normal subjects or those received treatment of gonadotrophins and/or other methods for induction of ovulation or superovulation to improve the yield of ovulated oocytes (ova). Multiple ova released from the ovaries travel through the fallopian tubes, which may be fertilized with sperms made available by artificial or normal insemination (copulation). The fertilized embryos divide and differentiate further into free preimplantation stage embryos at morula- and blastocyst-stages are deposited on the Absorption Capsule. These embryos, retrieved from the Absorption Capsule and may be processed by a variety of methods routinely utilized in the Assisted Reproductive procedures, including, screening for various genomic diseases, karyotype errors of trisomy and other chromosomal anomalies, and deleterious mutations. The screening procedures may involve Preimplantation Genetic Diagnosis (PGD) and Trophectoderm biopsy methods. Normal embryos free of disease potential are transferred to the mothers or surrogates for further in utero development. These procedures allow prevention of human birth defects and pre- and post-natal genomic diseases by selection of disease-free normal embryos for further in utero development, and possible cure of genomic diseases at this stage, in the future.

The present invention relates to methods and compositions for differentiating between absence of disease, endometriosis, and EAOC or serous ovarian cancer in a subject. It is based, at least in part, on the discovery that certain microRNAs are associated with each of these conditions.

Present invention provides a method for diagnosing and prognosing endometrial cancer in easy-to-access isolated samples by detecting the level of expression of one or more proteins. In particular from uterine fluid samples. The invention also provides kits comprising means for detecting said proteins for use in the diagnosis and prognosis of the disease.

The present disclosure relates to biosensors, kits and methods for detecting and/or quantifying lysophosphatidic acid (LPA) in a liquid sample such as a serum sample from a subject. The present disclosure also relates to linker compounds that are useful, for example, in the biosensors, kits and methods of the present disclosure and to methods for preparing a biosensor for detecting and/or quantifying lysophosphatidic acid (LPA) in a liquid sample.

The disclosure relates to use of the HE4/HE4a marker(s) to assess endometrial and uterine cancer in a patient. The disclosure also relates to using tumors marks for diagnosis, grading and staging of endometrial and uterine cancers. The disclosure also relates to determining prognosis and treatment effectiveness of a patient who has been diagnosed with endometrial or uterine cancer.

The present disclosure relates to methods and a kit for diagnosing, prognosing and/or monitoring a gynaecological disease, especially epithelial ovarian cancer, on the basis of altered glycosylation pattern of CA125. More specifically, said altered glycosylation pattern relates to that recognizable by MGL.

Present invention provides a method for diagnosing and prognosing endometrial cancer in easy-to-access isolated samples by detecting the level of expression of one or more proteins. In particular from uterine fluid samples. The invention also provides kits comprising means for detecting said proteins for use in the diagnosis and prognosis of the disease.